Cancer
Malignant Cervical Neoplasm
CI-CAN-00007992Explore in graph →
Top-level506 active trials4 approved drugs14 evidence items
Loading cancer entity…
Cancer
CI-CAN-00007992Explore in graph →
Clinical trials
1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06197126 | MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy | not yet recruiting | — | 200 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04889742 |
| Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) |
| not yet recruiting |
| Phase 2 |
| 110 |
| Charite University, Berlin, GermanyOTHER |
| 1 |
| Dec 26, 2023 |
| clinicaltrials |
| NCT06150222 | Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study(Retro-COSMOS) | not yet recruiting | — | 350 | Erasmus Medical CenterOTHER | 0 | Dec 1, 2023 | clinicaltrials |
| NCT06128460 | Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. | not yet recruiting | Phase 2 | 24 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT06149767 | Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer | not yet recruiting | Phase 2 | 26 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 29, 2023 | clinicaltrials |
| NCT06118463 | Study on AUNIP as a Novel Tumor Marker for Cervical Cancer | not yet recruiting | — | 300 | Lin YuanOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT06101966 | A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy | not yet recruiting | — | 500 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06062589 | AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer | not yet recruiting | — | 18 | Peking University Third HospitalOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT06039982 | A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer | not yet recruiting | — | 100 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06039891 | Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer | not yet recruiting | Phase 2 | 55 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2023 | clinicaltrials |
| NCT05799469 | Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 36 | Chongqing University Cancer HospitalOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04999696 | Minimally Invasive Therapy Versus Open Radical Hysterectomy for Management of Early Stage Cervical Cancer(MITOR) | not yet recruiting | N/A | 820 | Chang Gung Memorial HospitalOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05210270 | HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy(HYACINCT) | not yet recruiting | Phase 1 / Phase 2 | 55 | University of Santo Tomas Hospital, PhilippinesOTHER | 0 | Jan 31, 2023 | clinicaltrials |
| NCT05510830 | Diagnostic Cervical Conization for Persistent Infection or Integration of HPV | not yet recruiting | N/A | 250 | Tongji HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04976478 | Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma | not yet recruiting | — | 125 | Peking University Third HospitalOTHER | 1 | Jul 26, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 7, 2024source: clinicaltrials